ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ
ΚΛΙΝΙΚΗΣ ΜΙΚΡΟΒΙΟΛΟΓΙΑΣ

ESCMID
Affiliated Society

ESCMID STUDY GROUP FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE

# "SURVEYING AND COMBATING AMR IN THE HIGHLY ENDEMIC EAST AND SOUTH EUROPE AND MEDITERRANEAN BASIN"

## LOCATION

DIVANI CARAVEL
HOTEL
ATHENS GREECE

## DATE

20 TO 23
MAY 2026

THE CONFERENCE, WILL BE ORGANIZED BY ESGARS (ESCMID STUDY GROUP FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE) AND THE HELLENIC SOCIETY OF CLINICAL MICROBIOLOGY

## FINAL PROGRAMME

Congress Secretariat:
Imagine Congress & Travel
Mail: info@imaginecongress.gr
Phone: +30 210 3252520

# “Surveying and Combating AMR in the Highly Endemic East – South Europe and Mediterranean Basin”
# Athens, 20-23 May 2026
# Hotel Divani Caravel

## WELCOME LETTER

Dear Colleagues,

Antimicrobial resistance (AMR) is an extremely important issue for most countries worldwide, including the European and neighboring regions. However, the distribution of AMR is not even, with Central, West and North Europe to have much lower rates than East and South Europe. To focus on AMR in the hot spot regions of East and South Europe and Mediterranean basin, the ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS) and the Hellenic Society of Clinical Microbiology are organizing the International Conference "Surveying and combating AMR issues in the highly endemic East and South Europe and Mediterranean Basin". In this Conference we will try to raise the most crucial AMR problems in our regions, discuss about possible interventions and set up international collaborations. We wish that this is the first meeting of many more to come and that expanding knowledge will lead to better outcomes in the battle against AMR. All colleagues who are interested in AMR will be very welcome!

On behalf of the organizers,

Spyros Pournaras

Conference Chair

## Wednesday 20 May, Day 1

**Scientific Committee**

1. Ritu Banerjee
2. Sophie Baron
3. Georgios Chamilos
4. Stylianos Chatzipanagiotou
5. George Daikos
6. Adrian Egli
7. Önder Ergönül
8. Christian Giske
9. Stephan Goettig
10. Paul Higgins
11. Jaroslav Hrabak
12. Surbhi Malhotra-Kumar
13. Jacob Moran-Gilad
14. Efthymia Petinaki
15. Laurent Poirel
16. Jean-Marc Rolain
17. Fotini Paliogianni
18. Robert Leo Skov
19. Athanasios Tsakris
20. Sotirios Tsiodras
21. David van Duin
22. Timoleon-Achilleas Vyzantiadis
23. Theoklis Zaoutis
24. Raffaele Zarrilli

**Organizing Committee**

1. Spyros Pournaras
2. Lemonia Skoura
3. Olympia Zarkotou
4. Stavroula Antonopoulou
5. Maria Panopoulou
6. Eleftheria Trikka
7. Vasiliki Iliadi
8. Antonio Oliver
9. Yesim Besli
10. Iva Butic
11. Ini Adebyii

## SCIENTIFIC PROGRAMME

**08:00-09:00: Registrations**

**09:00-10:30 Educational course 1**

***Chairs**: Efthymia Petinaki, Maria Panopoulou*

- **One Health Surveillance of Antimicrobial Resistance: Integrating Humans, Animals, and the Environment**
  Marwan Osman, Lebanon
- **How to track the origin of antibiotic resistance genes?**
  Jaroslav Hrabak, Czech Republic
- **Bacteriophages therapy in the context of AMR**
  Joseph Meletiadis, Greece

**10:30-11:00 Coffee break**

**11:00-13:00 Symposium 1**

**Antibiotic Decision-Making and Stewardship Integration**

***Chairs:** Iraklis Tsangaris, Iva Butic*

- **Antibiotic Decision-Making in Critical Care: From Emergency Room to ICU**
  Jeroen Schouten, The Netherlands
- **Laboratory Algorithms for Rapid Detection of Resistance: Supporting Timely Stewardship Decisions**
  Olympia Zarkotou, Greece
- **Laboratory-Driven Integration of Infection Control and Stewardship: Bridging Surveillance with Clinical Practice**
  Yeşim Beşli, Türkiye
- **Integrating Infection Control and Antimicrobial Stewardship: A Synergistic Approach to Combat AMR**
  Konstantinos Thomas, Greece

**13:00-13:30 Satellite Symposium 1**

**13:30-14:00 Satellite Symposium 2**

**14:00-15:00 Lunch break**

**15:00-16:00 E-posters Session 1**

***Chairs:*** *Eleftheria Trikka, Vasiliki Iliadi*

**16:00-17:00—MediCA2C project presentation** (business meeting)
*MediCA2C project is an alliance between lab, experts and Universities in the Mediterranean basin supported by Aix-Marseille University, Institute Mediterranée Infection and Euromediterraean consortium of Universities Tethys*

**17:00-18:30 Symposium 2**

**AMR in ICU Settings: Regional and Clinical Insights**

***Chairs:*** *Önder Ergönül, Efstathia Perivolioti*

- **MDR Gram-Negative Bacteremia in the ICU: Duration, Resistance Profiles, and Treatment Outcomes**
  Dafna Yahav, Israel
- **Epidemiology and Resistance Mechanisms of *Escherichia coli* and *Klebsiella pneumoniae* in ICU in Balkan coiuntries**
  Alice Ghenea, Romania
- **Carbapenem Resistance and Antibiotic Use Patterns in Azerbaijani ICUs: Local Data and Regional Challenges**
  Aygun Israyilova, Azerbaijan

**18:30-19:00 Keynote Lecture 1**

***Chairs:*** *Theoklis Zaoutis, Maria Chatzidimitriou*

**Climate crisis and AMR: a dual threat**

Iva Butic, Croatia

**19:00-20:30: Opening Ceremony**

**08:30-10:00 Oral Session**

***Chairs**: Emmanuel Roilides, Angelos Pefanis*

**10:00-11:30 Educational course 2**

**How to evaluate**

***Chairs**: Jaroslav Hrabak, Olympia Zarkotou*

- **Novel AMR diagnostics**
  Thierry Naas, France
- **Antimicrobial Stewardship programs**
  David van Duin, North Carolina, USA
- **IPC interventions**
  Stephan Goettig, Germany

**11:30-12:00 Coffee break**

**12:00-12:30 Keynote Lecture 2**

***Chairs:** Antonio Oliver, Alessandra Carattoli*

**Implementation of Whole Genome Sequencing Data to support surveillance and combat AMR**

Andrei-Alexander Muntean, Romania

**12:30-13:30 Satellite Symposium 3**

**13:30-14:00 Satellite Symposium 4**

**14:00-14:30 Lunch break**

**14:30-15:30 E-posters Session 2**

***Chairs:** Konstantinos Thomas, Drosos Karageorgopoulos*

**15:30-17:00 Symposium 3**

***Chairs:*** *Anastasios Ioannidis, Jean-Marc Rolain*

**Applications and challenges of Artificial Intelligence in AMR, AMS and IPC**

- **Bacterial genomics in infection prevention and control: the role of artificial intelligence**
  Jacob Moran-Gilad, Israel
- Artificial Intelligence for AMR prediction
  Oliver Nolte, Switzerland
- **Artificial Intelligence supporting antibiotic decision making and antimicrobial stewardship**
  Belen Rodriguez, Spain

**17:00-19:00 Symposium 4**

***Chairs****: Sotirios Tsiodras, Gian Maria Rossolini*

**Future treatment options for infections related to drug-resistant bacteria**

- **Promising treatment opportunities against drug-resistant Gram negatives**
  Drosos Karageorgopoulos, UK
- **Optimized treatment options against tuberculosis in the Mediterraenan basin**
  Dimitrios Papaventsis, Greece
- **Antimicrobial Peptides as Next Generation Weapons Against Multidrug Pathogens**
  Burkhard Bechinger, France
- **New/novel/emerging vaccines against drug-resistant bacteria**
  **Rino Rappuoli, Italy,**

**19:00-19:30 Keynote Lecture 3**

***Chairs:*** *Stylianos Chatzipanagiotou, Antonios Markogiannakis*

**Factors associated with antibiotic resistance: the PharmacoMicrobioresistance paradigm**

Jean-Marc Rolain, France

**08:30-10:00 Oral Session**

***Chairs:*** *Vasiliki Papaevangelou, Polyxeni Karakosta*

**10:00-11:30: Educational course 3**

***Chairs****: Sophia Vourli, Laurent Poirel*

**Carbapenemase production across Mediterranean Basin: from bench to the bedside**

- Advances in carbapenemase detection in Enterobacterales
  Gian Maria Rossolini, Italy
- Trends in carbapenemase-producing *Pseudomonas aeruginosa*
  Antonio Oliver
- Current treatment options for carbapenem-resistant pathogens
  Garyfallia Poulakou

**11:30-12:00 Coffee break**

**12:00-13:00 Satellite Symposium 5**

**13:00-14:30 Symposium 5**

***Chairs****: Thierry Naas, Raffaele Zarrilli*

**Epidemiology and challenges for ESKAPE pathogens in the Mediterranean basin**

- **Current trends of antibiotic resistance**
  Alessandra Carattoli, Italy
- **Implementation of antibiotic stewardship in low- and middle-income countries**
  Souha Kanj, Lebanon
- **Circulation of Enterobacterales clones in the Mediterranean basin: a genomic approach**
  Sophie Baron, France

**14:30-15:00 Satellite Symposium 6**

**15:00-15:30: Lunch break**

**15:30-16:30 E-posters Session 3**

***Chairs:*** *Angeliki Poulou, Theofano Panagea*

**16:30-18:00 Symposium 6**

***Chairs:*** *Paul Higgins, Georgios Daikos*

**What is new in Carbapenem-resistant *Acinetobacter baumannii* epidemiology and management?**

- **Phenotypic and genomic epidemiology of carbapenem-resistant *Acinetobacter baumannii* in AMR hot spot regions**
  Paul Higgins, Germany
- **New beta-lactams active against carbapenem-resistant *Acinetobacter baumannii***
  Laurent Poirel, Switzerland
- **Cefiderocol versus standard therapy against carbapenem-resistant *Acinetobacter baumannii***
  Raffaele Zarrilli, Italy

**18:00-19:30: Symposium 7**

***Chairs****: Robert Leo Skov, Dimosthenis Makris*

**National Strategies and Surveillance Frameworks**

- **Advancing AMR Surveillance Through Laboratory Standards**
  Onur Karatuna, Sweden
- **Multidisciplinary Interventions Against Carbapenem-Resistant Bacteria in ICUs: Outcomes from a Lebanese Tertiary Center**
  Nisrine Haddad Sarkis, Lebanon
- **Implementing Stewardship Across Levels: Clinical Pathways, National Policy, and Big Data Analytics in Türkiye**
  Önder Ergönül, Türkiye

**19:30-20:00 Keynote Lecture 4**

***Chairs:*** *Konstantina Gartzonika, Joseph Meletiadis*

**Trends in antifungal resistance in East – South Europe**

Timoleon-Achilleas Vyzantiadis, Greece

**08:30-10:00 Oral Session**

***Chairs**: Michail Samarkos, Flora Kontopidou*

**10:00-12:00 Symposium 8**

***Chairs**: Lemonia Skoura, Tom Talbot*

**Successes, Innovations and Challenges in IPC: Lessons learned from GAIHN-AR program**

- **Monitoring and feedback to enhance environmental cleaning**
  Efthymia Protonotariou, Greece
- **Facilitators and barriers to implementation of IPC (A. Mixon)**
  Amanda Mixon, USA
- **Sustainability of IPC activities: opportunities and threats**
  Ritu Banerjee, USA
- **Engaging hospital leaders and governments**
  Tom Talbot, USA

**12:00-12:30 Coffee break**

**12:30-13:00 Keynote Lecture 5**

***Chairs**: Spyros Pournaras, Ritu Banerjee*

**Is behavior change feasible in highly endemic regions?**

Michael Borg, Malta

**13:00-13:30 Satellite Symposium 7**

**13:30-14:00 Satellite Symposium 8**

**14:00-15:00 Lunch break**

**15:00-17:00 Symposium 9**

**Closing the AMR Divide: Joint Programme Initiatives for the South Mediterranean and Middle East**

***Chairs:*** *Holger Rohde (EAASC), Mohamed Elhadidy (Egypt)*

- **Surveillance Gaps and Antimicrobial Resistance Burden in South Mediterranean and Middle East Countries: Policy-Relevant Pathways from Fragmented Data to Coordinated Euro-Mediterranean Action**

  Tomislav Mestrovic, Croatia

- **From Declaration to Action: how can we build the Mediterranean One Health Consortium through Concrete Regional Partnerships on AMR**

  Josette Najjar-Pellet, Lebanon

- **Equity and Ethics in AMR Control: The Role of Infectious Diseases and Clinical Microbiology Professional Societies in Low- and Middle-Income Settings**

  Robert Skov, Denmark

- **Strengthening Diagnostic Literacy Through Targeted Education: A Capacity-Building Strategy for AMR Control in the Euro-Mediterranean Region**

  Anna Both, Germany

At the end of the presentations, there will be a 40 minutes panel debate for the limitations existing in Low- and Middle-Income Settings

**17:00-17:30 Keynote Lecture 6**

***Chair**: Jean-Marc Rolain, Stavroula Antonopoulou*

**GLASS REPORT 2025 for East - South Europe and Mediterranean Basin**

Surbhi Malhotra-Kumar, Belgium

**17:30-19:00 Symposium 10**

***Chairs**: Kyriaki Tryfinopoulou, Surbhi Malhotra-Kumar*

**Resistance and Virulence-Related Risks: The Gram-Negative Threat**

- **Hypervirulent *Klebsiella Pneumoniae***

  Mohamed Elhadidy, Egypt
- **Radical changes in CPE epidemiology in Poland/Middle-Eastern Europe**

  Marek Gniadkowski, Poland
- **Tracking Resistance and Virulence in Foodborne Pathogens**

  Lourdes Migura-Garcia,Spain

**19:00-19:30 Keynote Lecture 7**

***Chair**: Fotini Paliogianni, Athanasios Michos*

**Is AMR in Gram-positives still a threat?**

Joseph Papaparaskevas, Greece

## End of the Conference

## CHAIRPERSONS - SPEAKERS

Stavroula Antonopoulou, Biopathologist, Clinical Microbiologist, NHS Director, Laboratory of Microbiology, Alexandra Hospital, Athens, Greece

Ritu Banerjee, Professor, Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, USA

Sophie Baron, Assistant Professor at Aix-Marseille University, Marseille, France

Burkhard Bechinger, Professor, Membrane Biophysics and NMR, Chemistry Institute UMR7177, University of Strasbourg/CNRS, Institut Universitaire de France, France

Yesim Besli, Clinical Microbiologist, Assistant Professor, American Hospital, Istanbul, Türkiye

Michael Borg, Professor, Department of Infection Control at Mater Dei Hospital in Malta and the National Antimicrobial Resistance Committee, Malta

Anna Both, Institut für Medizinische Mikrobiologie, Virologie und Hygiene Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Iva Butic, Clinical microbiologist at Zagreb University Hospital for Infectious Diseases, Zagreb, Croatia

Alessandra Carattoli, Department of Molecular Medicine, Sapienza University of Rome Rome Italy

George Chamilos, Professor of Microbiology, University of Crete, Heraclion, Greece

Maria Chatzidimitriou, Prof. of Microbiology and Immunology, Medical Biopathologist, International Hellenic University

Stylianos Chatzipanagiotou, Professor of Microbiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Georgios Daikos, Emeritus Professor of Internal Medicine-Infectious Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, General Hospital Mitera, Athens, Greece

Mohamed Elhadidy, Professor of Biomedical Sciences, Director of Center for Genomics (CG)

Zewail City of Science, Technology, and Innovation, Giza, Egypt

Önder Ergönül, Professor, Chair of the Infectious Diseases and Clinical Microbiology in Koç University, School of Medicine, Istanbul, Turkiye

Konstantina Gartzonika, Biopathologist, Clinical Microbiologist, Professor of Microbiology, School of Medicine, University of Ioannina, Ioannina, Greece

Alice Ghenea, Professor of Clinical Microbiology, Department of Microbiology University of Medicine and Pharmacy of Craiova, Craiova, Romania

Marek Gniadkowski, Department of Molecular Microbiology, National Medicines Institute, Warsaw, Poland

Nisrine Haddad Sarkis, Senior Antimicrobial Stewardship Pharmacist, American University of Beirut Medical Center, Beirut, Lebanon

Paul Higgins, Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne, University of Cologne, Cologne, Germany

Jaroslav Hrabak, Professor, Department of Microbiology & Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czech Republic

Vasiliki Iliadi, Biopathologist, Clinical Microbiologist, NHS Director Laikon General Hospital, Athens, Greece

Anastasios Ioannidis, Biopathologist, Assistant Professor of Microbiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Aygun Israyilova, Microbiologist, Senior Researcher at the Microbiology and Virology Research Laboratory of the Center for Excellence in Research, Development and Innovation at Baku State University, Baku, Azerbaijan

Souha Kanj, Professor of Medicine and Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon

Drosos Karageorgopoulos, MD, PhD, MPH, Infectious Diseases Consultant, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Polyxeni Karakosta, Biopathologist, NHS Consultant, Attikon University Gneral Hospital, Athens, Greece

## CHAIRMEN – SPEAKERS

Onur Karatuna, Associate Professor, EUCAST Development Laboratory, Clinical Microbiology, Växjö Hospital, Växjö, Sweden

Flora Kontopidou, Infectious Diseases Physician, General Hospital Mitera, Athens, Greece

Dimosthenis Makris, Professor of Intensive Care Unit, School of Medicine, University of Thessaly, Larissa, Greece

Surbhi Malhotra-Kumar, Professor, Universiteit Antwerpen, Belgium

Antonios Markogiannakis, Clinical Pharmacist, Laikon General Hospital, Athens, Greece

Joseph Meletiadis, Associate Professor of Mycology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Tomislav Mestrovic, University North, University centre Varazdin, Varazdin, Croatia Institute for Health Metrics and Evaluation and the Department of Health Metrics Sciences, University of Washington School of Medicine, Seattle, USA

Lourdes Migura-Garcia, Institute of Agrifood Research and Technology (IRTA), Animal Health Research Center (CReSA), Spain

Athanasios Michos, Professor of Pediatric Infectious Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Jacob Moran-Gilad, ESCMID Global Programme Director, Professor of Microbiology, Ben-Gurion University of the Negev, Israel

Andrei-Alexander Muntean, MD, Carol Davila University of Medicine and Pharmacy, Romania

Thierry Naas, Service de Bactériologie, Hopital Bicêtre, AP-HP Université Paris-Saclay, Le Kremlin-Bicêtre, France

Josette Najjar-Pellet, MPH, PhD, Middle East North Africa Regional Director, Fondation Mérieux–Middle East North Africa, Beirut, Lebanon

Oliver Nolte, Professor, Specialist in laboratory medicine FAMH, Head of Diagnostics Department, Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland

Antonio Oliver, Microbiology Department of Hospital Son Espases, IdISBa, CIBERINFEC, Palma de Mallorca, Spain

Marwan Osman, Department of Neurosurgery, Yale School of Medicine

Fotini Paliogianni, Biopathologist, Clinical Microbiologist, Professor of Microbiology, School of Medicine, University of Patras, Patras, Greece

Theofano Panagea, Biopathologist, Clinical Microbiologist, NHS Director, Laboratory of Microbiology, Amalia Fleming Hospital, Athens, Greece

Maria Panopoulou, Biopathologist, Clinical Microbiologist, Professor of Microbiology, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece

Vasiliki Papaevangelou, Professor of Pediatric Infectious Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Joseph Papaparaskevas, Biopathologist, Professor of Microbiology-Bacteriology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Dimitrios Papaventsis, Biopathologist, Clinical Microbiologist, NHS Senior Consultant, Laboratory of Microbiology, Sotiria General Hospital of Thoracic Diseases, Athens, Greece

Angelos Pefanis, M.D., Ph.D., Consultant in Internal Medicine and Infectious Diseases, Deputy Chairman of the Scientific Council for the Approval of Drugs for Human Use, National Medicines Agency, Deputy Chairman of the National Antibiogram Committee, Board Member of the "Hellenic Society of Infectious Diseases"

Efstathia Perivolioti, Biopathologist, Clinical Microbiologist, NHS Director, Laboratory of Microbiology, Evangelismos General Hospital, Athens, Greece

Efthymia Petinaki, Biopathologist, Clinical Microbiologist, Professor of Microbiology, School of Medicine, University of Thessaly, Larissa, Greece

Laurent Poirel, Medical and Molecular Microbiology Unit, Department Oncology-Microbiology-Immunology, Faculty of Science and Medicine, University of Fribourg, Director, National Reference Center for Emerging Antibiotic Resistance – NARA, Fribourg, Switzerland

Garyfallia Poulakou, Associate Professor of Medicine and Infectious Diseases, Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

## CHAIRPERSONS – SPEAKERS

Angeliki Poulou, Biopathologist, Clinical Microbiologist, NHS Consultant, Laboratory of Microbiology, Serres General Hospital, Serres, Greece

Spyros Pournaras, Biopathologist, Clinical Microbiologist, Professor of Microbiology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Efthymia Protonotariou, Biopathologist, Clinical Microbiologist, Associate Professor of Microbiology, AHEPA University General Hospital, School of Medicine, Aristotelian University of Thessaloniki, Thessaloniki, Greece

Emmanuel Roilides, Emeritus Professor of Pediatric Infectious Diseases, School of Medicine, Aristotelian University of Thessaloniki, Thessaloniki, Greece

Jean-Marc Rolain, President of MediCA2C, Aix-Marseille University, Marseille, France

Belén Rodríguez-Sánchez, Senior Researcher, Institute of Health Research Gregorio

Marañón, University Hospital Gregorio Marañón, Madrid, Spain

Gian Maria Rossolini, Professor of Microbiology and Clinical Microbiology, Department of Experimental and Clinical Medicine, University of Florence, Microbiology and Virology Unit, Florence Careggi University Hospital, Italy

Michail Samarkos, Professor of Internal Medicine-Infectious Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Jeroen Schouten, Internist and Intensivist, Radboud University Medical Centre, The Netherlands

Lemonia Skoura, Biopathologist, Clinical Microbiologist, Professor of Microbiology, AHEPA University General Hospital, School of Medicine, Aristotelian University of Thessaloniki, Thessaloniki, Greece

Robert Leo Skov, ESCMID President, Statens Serum Institute, Copenhagen, Denmark

Tom Talbot, Professor of Medicine, Vanderbilt University School of Medicine;

Chief Hospital Epidemiologist, VUMC, Nashville, TN, USA

Konstantinos Thomas, Assistant Professor of Internal Medicine - Infectious Diseases, Attikon Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Eleftheria Trikka, Biopathologist, Clinical Microbiologist, Greece

Kyriaki Tryfinopoulou, Biopathologist, Assistant Professor of Microbiology, University of Crete, Heraclion, Greece

Athanasios Tsakris, Professor of Microbiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Iraklis Tsangaris, Professor of Intensive Care Unit, Attikon Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Sotirios Tsiodras, Professor of Internal Medicine-Infectious Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Dafna Yahav, Professor, infectious diseases unit, Sheba medical center, Ramat-Gan, Israel

Timoleon-Achilleas Vyzantiadis, Professor of Microbiology, School of Medicine, Aristotelian University of Thessaloniki, Thessaloniki, Greece

David van Duin, Professor of Medicine, Director, Immuno-compromised Host Infectious Diseases Section, University North Carolina, Chapel Hill, USA

Sophia Vourli, Senior Researcher, Head of Laboratory of Bacteriology and Antimicrobial Resistance Mechanisms, Institute of Biosciences & Applications, NCSR "Demokritos", Athens, Greece

Olympia Zarkotou, Biopathologist, Clinical Microbiologist, NHS Director, Laboratory of Microbiology, Tzaneio General Hospital, Piraeus, Greece

Theoklis Zaoutis, Professor of Pediatric Infectious Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Raffaele Zarrilli, Professor, Department of Public Health, University of Naples Federico II, Naples, Italy

## INFORMATION

**Venue:** **DIVANI CARAVEL HOTEL**
2, Vas. Alexandrou 161 21 Athens
Phone: +30 210 7207000

**Language:** English

**Certificate of Attendance:** Certificates will be sent after the conference. Attendance at least 60% of the conference is required.

**EACCME Credits :** Conference will be accredited by 23.5 EACCME credits.

**Congress Organizer:**

Imagine Congress & Travel
9, Kolokotroni Street, 105 62 Athens - Greece
Phone: +30 210 3252520
Mail: info@imaginecongress.gr

**On behalf of the Conference Organizing Committee, we would like to express our sincere gratitude to the Congress sponsors:**

Abbott
ΠΑΥΛΟΣ ΑΡΝΑΟΥΤΗΣ
BD
BioAnalytica BIOTECHNOLOGY SYSTEMS
BIOMÉRIEUX
COYOTE
elta90 MGR
J. M. KYRIAKIDIS S.A.
NDD NEW DIAGNOSTIC DIMENSION
MAGIRAS DIAGNOSTICS
ΑΡΗΣ ΜΑΝΤΖΩΡΟΣ ΑΕ
MEDICAL TRADE INTERNATIONAL
Menarini Hellas
MENARINI diagnostics
NG·BIOTECH LABORATOIRES
SIEMENS Healthineers
VARELAS S.A. CHEMICALS AND DIAGNOSTICS
P. Zafiropoulos s.a. Diagnostica




# QUOFENIX®
## delafloxacin

**Το QUOFENIX® ενδείκνυται για τη θεραπεία των παρακάτω λοιμώξεων σε ενήλικες:**

- **οξέων βακτηριακών λοιμώξεων του δέρματος και των μαλακών μορίων (ABSSSI)***
- **πνευμονία της κοινότητας (ΠΚ)***

**όταν η χρήση άλλων αντιβακτηριακών παραγόντων που συνιστώνται συνήθως για την αρχική θεραπεία αυτών των λοιμώξεων θεωρείται ακατάλληλη (βλέπε παραγράφους 4.4 και 5.1 από την Π.Χ.Π.).**

**Θα πρέπει να λαμβάνονται υπόψη οι επίσημες οδηγίες σχετικά με την κατάλληλη χρήση αντιβακτηριακών παραγόντων.**

Λ.Τ.: 708,00 €
Ν.Τ.: 561,25 €

*Καλύπτεται από τα ασφαλιστικά ταμεία μόνο η ένδειξη οξέων βακτηριακών λοιμώξεων του δέρματος και των δερματικών δομών (ABSSSI).

**QUOFENIX® 300 mg**
delafloxacin

**(κόνις για πυκνό σκεύασμα για παρασκευή διαλύματος προς έγχυση)**

**ΔΟΣΟΛΟΓΙΑ ΚΑΙ ΤΡΟΠΟΣ ΧΟΡΗΓΗΣΗΣ:** Η συνιστώμενη δόση είναι 300 mg δελαφλοξασίνης κάθε 12 ώρες χορηγούμενη για ένα διάστημα 60 λεπτών μέσω ενδοφλέβιας έγχυσης. Η μετάβαση σε από του στόματος λαμβανόμενο δισκίο δελαφλοξασίνης 450 mg κάθε 12 ώρες είναι δυνατή κατά τη διακριτική ευχέρεια του ιατρού. Η συνολική διάρκεια της θεραπείας είναι 5 έως 14 ημέρες για ABSSSI και 5 έως 10 ημέρες για ΠΚ.
**ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ ΚΑΙ ΣΥΣΚΕΥΑΣΙΑ:** Διάφανα γυάλινα φιαλίδια τύπου Ι των 20 ml, εφοδιασμένα με ελαστικά πώματα εισχώρησης τύπου Ι των 20 mm και αποσπώμενα πώματα των 20 mm. Μέγεθος συσκευασίας: 10 φιαλίδια.
**ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Κάθε φιαλίδιο περιέχει δελαφλοξασίνη μεγλουμίνη ισοδύναμη με 300 mg δελαφλοξασίνης. Μετά από την ανασύσταση, κάθε ml περιέχει 25 mg δελαφλοξασίνης.
**ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: «Περιορισμένη ιατρική συνταγή. Η έναρξη της θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται εκτός νοσοκομείου, υπό την παρακολούθηση ιατρού. Αιτιολογημένη συνταγή φυλασσόμενη επί διετία».**

Quofenix® 300mg (IV) Π.Χ.Π. (02/2025).

**QUOFENIX® 450 mg**
delafloxacin

**(δισκία)**

**ΔΟΣΟΛΟΓΙΑ ΚΑΙ ΤΡΟΠΟΣ ΧΟΡΗΓΗΣΗΣ:** Το συνιστώμενο σχήμα της δελαφλοξασίνης είναι 450 mg από του στόματος λαμβανόμενα κάθε 12 ώρες για συνολική διάρκεια 5 έως 14 ημερών για ABSSSI και 5 έως 10 ημέρες για ΠΚ κατά τη διακριτική ευχέρεια του ιατρού.
Τα δισκία δελαφλοξασίνης μπορούν να λαμβάνονται με ή χωρίς τροφή.
**ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Κάθε δισκίο περιέχει δελαφλοξασίνη μεγλουμίνη ισοδύναμη με 450 mg δελαφλοξασίνης.
**ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ ΚΑΙ ΣΥΣΚΕΥΑΣΙΑ:** Κυψέλες (blisters) από επιστρωμένο φύλλο αλουμινίου/αλουμινίου. Μέγεθος συσκευασίας: 10 δισκία.
**ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: «Αιτιολογημένη ειδική συνταγή φυλασσόμενη επί διετία».**
**Υπόδειγμα της αιτιολογημένης ειδικής συνταγής επισυνάπτεται στην αριθμ. 25767/28-3-2018, εγκύκλιο του ΕΟΦ.**

Quofenix® 450mg (Tabs) Π.Χ.Π. (02/2025).

GR-QUO-3-01-2026

Για περισσότερες πληροφορίες και τις Π.Χ.Π. παρακαλούμε απευθυνθείτε στην εταιρεία:

Πριν τη συνταγογράφηση παρακαλούμε συμβουλευτείτε τις Περιλήψεις Χαρακτηριστικών των Προϊόντων σκανάροντας το αντίστοιχο QR code

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

Menarini Hellas

Menarini Hellas A.E. - Πάτμου 16-18, 151 23, Μαρούσι, Αττική
Τ.: 210 8316111-13, F.: 210 8317343
info@menarini.gr, www.menarini.gr